Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Antioxidant extracts of G.biloba leaves may protect cells from radiation damage

Antioxidant extracts of the leaves of the Gingko biloba tree may protect cells from radiation damage, according to a study published in the International Journal of Low Radiation. The discovery may one day be used to help reduce side effects in cancer patients undergoing radiotherapy.

20 Oct 2009

Breakthrough discovery by scientists may lead to a new treatment for Alzheimer's Disease

A breakthrough discovery by scientists from the Mayo Clinic in Jacksonville, FL, may lead to a new treatment for Alzheimer's Disease that actually removes amyloid plaques-considered a hallmark of the disease-from patients' brains.

19 Oct 2009

Researchers find the genetic mutation that is linked with changes in brain development

For decades, scientists have thought the faulty neural wiring that predisposes individuals to behavioral disorders like autism and psychiatric diseases like schizophrenia must occur during development. Even so, no one has ever shown that a risk gene for the disease actually disrupts brain development.

19 Oct 2009

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

Pfizer Inc today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets.

19 Oct 2009

FDA approves continuation of the fourth 6-month open label extension of PRX-03140

The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer's Disease. The patient was enrolled initially in a two week Phase 2a study in August 2007 where she received 100 mg per day of PRX-03140 in combination with her normal daily dose of Aricept(10 mg).

19 Oct 2009

Studies find frail seniors often get poor, futile care

Two studies published in the New England Journal of Medicine find that some medical care, especially at the end of life, may be a poor choice for feeble seniors. They also show the importance of palliative care over aggressive treatment for certain patients.

19 Oct 2009

Novel HIV drug to be studied in cell cultures and patients

A $6 million, five-year federal grant to The Children's Hospital of Philadelphia Research Institute will enable researchers to investigate a novel approach in treating HIV infection---a unique class of drugs focused on developing therapies for psychological and neurological effects in AIDS.

19 Oct 2009

APP balance critical for normal neuronal development

New data about amyloid precursor protein, or APP, a protein implicated in development of Alzheimer's disease, suggests it also may have a positive role -- directly affecting learning and memory during brain development. So is APP good or bad? Researchers at Georgetown University Medical Center say both, and that a balance of APP is critical.

19 Oct 2009

Windsor Place of Wilmington opens to welcome new residents

Windsor Place of Wilmington, a premier assisted living residence for seniors, announced today that it will welcome residents this month. Windsor Place has 87 distinctive luxury suites. A portion are designated for individuals with memory impairment due to Alzheimer’s disease and related disorders.

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Study: Psychiatrists can distinguish competent defendants from incompetent ones

Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?

14 Oct 2009

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

Integrated Diagnostics launched officially today with more than $30 million in funding. A pre-eminent team of scientists and investors are behind the company, which was founded by renowned biotechnology innovator Dr. Leroy Hood. Integrated Diagnostics will focus on developing personalized and preventive diagnostics based on breakthroughs using genomic and proteomic technologies to identify organ-specific proteins.

14 Oct 2009

NIH awards research grants for NYU Langone Medical Center

NYU Langone Medical Center has been awarded more than $30 million in research grants from the National Institute of Health (NIH) for 86 research projects being conducted at NYU School of Medicine across a broad range of basic science and clinical departments.

14 Oct 2009

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Metabolic Solutions Development Company (MSDC) announced today that it has received a $100,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF) to support the evaluation of PPAR-sparing insulin sensitizers as a potential treatment for Alzheimer's disease.

14 Oct 2009

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Vanda Pharmaceuticals Inc. announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults.

14 Oct 2009

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

14 Oct 2009

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

The National Institutes of Health (NIH) has awarded a "Grand Opportunity" grant of $3.7 million to a consortium formed with the Gladstone Institute of Neurological Disease (GIND) and the Taube-Koret Center for Huntington's Disease Research to use stem cell technology to better understand Huntington's disease (HD) and to develop potential therapies.

14 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Discovery opens new possibility of designing drugs for amyotrophic lateral sclerosis

Researchers at Lund University, Sweden, have taken a snapshot of proteins changing shape, sticking together and creating structures that are believed to trigger deadly processes in the nervous system. The discovery opens the possibility of designing drugs for a devastating neurological disease, ALS.

13 Oct 2009

New mouse models resembles human ALS; may provide important tool for screening new drugs

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Antioxidant extracts of G.biloba leaves may protect cells from radiation damage

Breakthrough discovery by scientists may lead to a new treatment for Alzheimer's Disease

Researchers find the genetic mutation that is linked with changes in brain development

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

FDA approves continuation of the fourth 6-month open label extension of PRX-03140

Studies find frail seniors often get poor, futile care

Novel HIV drug to be studied in cell cultures and patients

APP balance critical for normal neuronal development

Windsor Place of Wilmington opens to welcome new residents

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Study: Psychiatrists can distinguish competent defendants from incompetent ones

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

NIH awards research grants for NYU Langone Medical Center

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

Johnson & Johnson announces financial results for the third quarter of 2009

Discovery opens new possibility of designing drugs for amyotrophic lateral sclerosis

New mouse models resembles human ALS; may provide important tool for screening new drugs

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in